There has been a lot of interest in a new treatment called Orforglipron. But what is it, how does it differ from existing treatments such as Wegovy and Mounjaro, and why could it matter for people on a weight loss journey?
A new type of GLP-1 medication
Medicines such as Wegovy (semaglutide) and Mounjaro (tirzepatide) are known as GLP-1 receptor agonists. They mimic a natural gut hormone that helps control appetite and blood sugar levels, which in turn can support weight loss.
At present, these treatments are only available as weekly injections. For many people, that can feel like a barrier.
Orforglipron is different. It belongs to the same GLP-1 family but is being developed as a once-a-day pill. You can take it without fasting or water restrictions, which makes it much simpler. For anyone who has hesitated over injections, that convenience could be a turning point.
What the research tells us
Eli Lilly, the company behind Mounjaro, has been testing Orforglipron in large Phase 3 trials.
- In type 2 diabetes (ACHIEVE-3 trial): Orforglipron was compared with the existing GLP-1 pill Rybelsus. Results showed that people on Orforglipron, especially at higher doses, saw greater improvements in blood sugar and lost more weight on average.
- In obesity (ATTAIN-1 trial): For people without diabetes, results after 72 weeks were encouraging. On the highest dose, participants lost around 12% of their body weight, close to the levels achieved with injectable GLP-1 treatments.
Side effects were similar to those already seen with GLP-1 medicines, such as nausea or stomach upset, and overall safety looked in line with expectations.
Who might be able to take it?
Currently in the UK, GLP-1 treatments such as Wegovy and Mounjaro are licensed for people with a body mass index (BMI) of 30 or above, or for those with a BMI of 27 and above if they also have a weight-related health condition.
Early trial data suggests Orforglipron could potentially be prescribed more broadly, to people with a BMI of 27 and above regardless of other conditions. That would open access to many more individuals classed as overweight rather than waiting until they meet the definition of obesity.
There is also interest in whether Orforglipron could help with long-term weight maintenance. For example, someone might reach their goal weight with an injectable GLP-1 and then move onto Orforglipron to maintain their results more cost-effectively.
Why this matters
The main difference between Orforglipron and today’s GLP-1 medications is the form it takes. Instead of a weekly injection, it’s a daily tablet. For many, that change could make starting and sticking with treatment much easier.
But it’s important to remember that weight loss medication is not a quick fix. These treatments are designed to be part of a longer-term programme, alongside healthy lifestyle changes and personalised support. At CheqUp, that support comes through our Health Coaches and digital tools that help members build sustainable habits.
When will Orforglipron be available?
Orforglipron has not yet been approved by regulators. Eli Lilly has said it plans to submit trial results to health authorities in the US, UK and EU. If all goes smoothly, the earliest possible launch date looks to be 2026. However, this will depend on regulatory review and approval.
The CheqUp perspective
Orforglipron is shaping up to be the first daily GLP-1 pill that could rival injections for weight loss. It may expand access to treatment and offer a new choice for people who prefer tablets over jabs.
For now, it remains under review. At CheqUp, we’ll continue to monitor developments closely so we can keep our members informed and ready to make the choices that work best for them.
